Volume 21, Issue 6 p. 656
Mutation in Brief
Free Access

Fourteen novel OPA1 mutations in autosomal dominant optic atrophy including two de novo mutations in sporadic optic atrophy

Olivier Baris

Olivier Baris

INSERM E 00-18, Laboratoire de Biochimie et Biologie Moléculaire, CHU Angers, France

The first two authors contributed equally to this work.

Search for more papers by this author
Cécile Delettre

Cécile Delettre

INSERM U254, Montpellier, France

The first two authors contributed equally to this work.

Search for more papers by this author
Patrizia Amati-Bonneau

Corresponding Author

Patrizia Amati-Bonneau

INSERM E 00-18, Laboratoire de Biochimie et Biologie Moléculaire, CHU Angers, France

INSERM E 00-18, Laboratoire de Biochimie et Biologie Moléculaire, CHU d'Angers, 49033 Angers, FranceSearch for more papers by this author
Marie-Odile Surget

Marie-Odile Surget

INSERM U254, Montpellier, France

Search for more papers by this author
Jean-François Charlin

Jean-François Charlin

Service d'Ophtalmologie, CHU Rennes, France

Search for more papers by this author
Antoine Catier

Antoine Catier

Service d'Ophtalmologie, CHU Rennes, France

Search for more papers by this author
Laurence Derieux

Laurence Derieux

Service d'Ophtalmologie, CHU Rennes, France

Search for more papers by this author
Jean-Laurent Guyomard

Jean-Laurent Guyomard

Service d'Ophtalmologie, CHU Rennes, France

Search for more papers by this author
Hélène Dollfus

Hélène Dollfus

Service de Génétique Médicale, CHU Strasbourg, France

Search for more papers by this author
Philippe Jonveaux

Philippe Jonveaux

Service de Génétique Médicale, CHU Nancy, France

Search for more papers by this author
Carmen Ayuso

Carmen Ayuso

Servicio de Genetica, Fundacion Jiménez Diaz, Madrid, Spain

Search for more papers by this author
Irene Maumenee

Irene Maumenee

The Wilmer Eye Institute, Baltimore, Maryland

Search for more papers by this author
Birgit Lorenz

Birgit Lorenz

Klinikum für Augenheilkunde Regensburg, Germany

Search for more papers by this author
Shehla Mohammed

Shehla Mohammed

DNA Laboratory, Genetics Centre, Guy's Hospital, London, United Kingdom

Search for more papers by this author
Yves Tourmen

Yves Tourmen

INSERM E 00-18, Laboratoire de Biochimie et Biologie Moléculaire, CHU Angers, France

Search for more papers by this author
Dominique Bonneau

Dominique Bonneau

Service de Génétique Médicale, CHU Angers, France

Search for more papers by this author
Yves Malthièry

Yves Malthièry

INSERM E 00-18, Laboratoire de Biochimie et Biologie Moléculaire, CHU Angers, France

Search for more papers by this author
Christian Hamel

Christian Hamel

INSERM U254, Montpellier, France

Search for more papers by this author
Pascal Reynier

Pascal Reynier

INSERM E 00-18, Laboratoire de Biochimie et Biologie Moléculaire, CHU Angers, France

Search for more papers by this author
First published: 23 September 2003
Citations: 46

Communicated by Arnold Munnich

Online Citation: Human Mutation, Mutation in Brief #623 (2003) Online http://www.interscience.wiley.com/humanmutation/pdf/mutation/623.pdf

Abstract

The OPA1 gene, encoding a dynamin-related GTPase that plays a role in mitochondrial biogenesis, is implicated in most cases of autosomal dominant optic atrophy (ADOA). Sixty-nine pathogenic OPA1 mutations have been reported so far. Most of these are truncating mutations located in the GTPase domain coding region (exons 8-16) and at the 3′-end (exons 27-28). We screened 44 patients with typical ADOA using PCR-sequencing. We also tested 20 sporadic cases of bilateral optic atrophy compatible with ADOA. Of the 18 OPA1 mutations found, 14 have never been previously reported. The novel mutations include one nonsense mutation, 3 missense mutations, 6 deletions, one insertion and 3 exon-skipping mutations. Two of these are de novo mutations, which were found in 2 patients with sporadic optic atrophy. The recurrent c.2708_2711delTTAG mutation was found in 2 patients with a severe congenital presentation of the disease. These results suggest that screening for OPA1 gene mutations may be useful for patients with optic atrophy who have no affected relatives, or when the presentation of the disease is atypical as in the case of early onset optic atrophy. © 2003 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.